Condition category
Respiratory
Date applied
02/08/2002
Date assigned
02/08/2002
Last edited
06/09/2007
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

MD Heribert Staudinger

ORCID ID

Contact details

Medical officer
Schering-Plough Research Institute (SPRI)
2015 Galloping Hill Road
K-15-4
Kenilworth
NJ 07033-0530
United States of America

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

C98-001

Study information

Scientific title

Acronym

Study hypothesis

Not provided at time of registration

Ethics approval

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Condition

Seasonal allergic rhinitis

Intervention

Patients randomly assigned once-daily (QD) SCH34117 at doses of 2.5, 5, 7.5, 10, or 20 mg versus placebo for two weeks.

Intervention type

Drug

Phase

Not Specified

Drug names

SCH34117

Primary outcome measures

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/04/1998

Overall trial end date

01/06/1998

Reason abandoned

Eligibility

Participant inclusion criteria

Subjects 12 years or older with a two-year documented history of seasonal allergic rhinitis and otherwise in good health

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

1026

Participant exclusion criteria

Not provided at time of registration

Recruitment start date

01/04/1998

Recruitment end date

01/06/1998

Locations

Countries of recruitment

United States of America

Trial participating centre

Medical officer
Kenilworth
NJ 07033-0530
United States of America

Sponsor information

Organisation

Schering-Plough Research Institute (SPRI) (USA)

Sponsor details

2015 Galloping Hill Road
K-15-4
Kenilworth
NJ 07033-0530
United States of America

Sponsor type

Industry

Website

http://www.schering-plough.com/rd/rd02_research.html

Funders

Funder type

Industry

Funder name

Schering-Plough Research Institute (SPRI) (USA)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Results in http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=12162793

Publication citations

  1. Results

    Salmun LM, Lorber R, 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]., BMC Fam Pract, 2002, 3, 14.

Additional files

Editorial Notes